Johnston, Jenessa N. http://orcid.org/0000-0003-2986-3179
Kadriu, Bashkim http://orcid.org/0000-0002-3809-9451
Kraus, Christoph
Henter, Ioline D.
Zarate, Carlos A. Jr
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857, ZIAMH002857, ZIAMH002857, ZIAMH002857, ZIAMH002857)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 1 April 2023
Revised: 8 May 2023
Accepted: 1 June 2023
First Online: 20 June 2023
Competing interests
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. BK is now a full-time employee and shareholder of Jazz Pharmaceuticals. All other authors have no conflict of interest to disclose, financial or otherwise.